Data analyzed from three centers
Test helpful for SLN-negative, stage I to IIA and thin tumors
Earlier detection of certain cancers a likely result
Toward detailed, personalized maps of identified and interpreted genomic variation
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Refractory patients respond to combination therapy
First agent in a new class of noncytotoxic cancer drugs
Understanding resistance in PARP inhibitor therapy
More time on drug may be needed
Data may lead to better treatment
Know Your Tumor initiative matches treatments with patients
Advertisement
Advertisement